Altimmune, Inc. (ALT) vs Monopar Therapeutics Inc. (MNPR)

Altimmune, Inc. and Monopar Therapeutics Inc. are both Biotechnology companies. Altimmune, Inc. and Monopar Therapeutics Inc. are of similar size ($602.8M and $593.3M). Across the 10 metrics below, Monopar Therapeutics Inc. leads on 8 and Altimmune, Inc. on 2.

Valuation

Metric ALT MNPR Biotechnology median
P/E n/m n/m 7.88
P/S 12,336.04 n/m 11.47
P/B 1.20 5.56 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 6,007.86 n/m 10.73
Earnings yield (25.49%) (2.55%) (28.84%)
Free cash flow yield (13.53%) (1.67%) (23.03%)

Profitability

Metric ALT MNPR Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (28.87%) (19.50%) (57.72%)
Return on assets (25.58%) (18.90%) (49.22%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT MNPR Biotechnology median
Revenue growth (TTM) 130.00% — 5.64%
EPS growth (last fiscal year) 25.37% 54.99% —
Revenue growth, 5-year CAGR (65.33%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT MNPR Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 33.56 4.73
Net debt to EBITDA 2.49 8.06 0.96

Dividend

Metric ALT MNPR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALT MNPR Biotechnology median
Market cap 593.28m 602.75m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack